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Abstract
Celiac disease is a chronic intestinal disease caused by intolerance to gluten. It is characterized by
immune-mediated enteropathy, associated with maldigestion and malabsorption of most nutrients
and vitamins. In predisposed individuals, the ingestion of gluten-containing food such as wheat and
rye induces a flat jejunal mucosa with infiltration of lymphocytes. The main symptoms are: stomach
pain, gas, and bloating, diarrhea, weight loss, anemia, edema, bone or joint pain. Prevalence for
clinically overt celiac disease varies from 1:270 in Finland to 1:5000 in North America. Since celiac
disease can be asymptomatic, most subjects are not diagnosed or they can present with atypical
symptoms. Furthermore, severe inflammation of the small bowel can be present without any
gastrointestinal symptoms. The diagnosis should be made early since celiac disease causes growth
retardation in untreated children and atypical symptoms like infertility or neurological symptoms.
Diagnosis requires endoscopy with jejunal biopsy. In addition, tissue-transglutaminase antibodies
are important to confirm the diagnosis since there are other diseases which can mimic celiac
disease. The exact cause of celiac disease is unknown but is thought to be primarily immune
mediated (tissue-transglutaminase autoantigen); often the disease is inherited. Management
consists in life long withdrawal of dietary gluten, which leads to significant clinical and histological
improvement. However, complete normalization of histology can take years.
Disease name and synonyms
Celiac disease (CD) in children and celiac sprue in adults
are probably the same disorder with the same pathogene-
sis. The synonyms are: Coeliac disease (British spelling) –
Celiac sprue – Nontropical sprue-Gluten-sensitive enter-
opathy – Idiopathic steatorrhea
Definition
Celiac disease is a chronic intestinal disease mostly associ-
ated with malabsorption caused by intolerance to gluten.
It is characterized by immune-mediated enteropathy (vil-
lous flattening), resulting in maldigestion and malabsorp-
tion. Clinical and histological improvement can be
obtained after withdrawal of dietary gluten.
Differential diagnosis
Celiac disease is characterized by malabsorption and vil-
lous atrophy. However, diseases other than CD can cause
marked villous flattening and increased intraepithelial
lymphocytes (IEL) [1]. Differential diagnosis is of special
importance for subjects in whom CD is suspected and
who have negative serology. The following diseases,
which can have similar features, must be ruled out [1-4]:
• Tropical sprue
• Collagenous colitis
• Whipple's disease
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• Giardiasis
• Viral enteritis
• AIDS
• Crohn's disease of the small intestine
• Small intestinal lymphoma
• Carbohydrate intolerance, cow's milk intolerance
• Autoimmune enteropathy
• Graft-vs-host disease
• Radiation damage
Epidemiology
Prevalence of clinically overt celiac disease varies from 1/
270 in Finland to 1/5,000 in North America. However,
since celiac disease can be asymptomatic, most subjects
are not diagnosed or they can present with atypical symp-
toms. In epidemiological studies aimed to assess CD prev-
alence, large cohorts in North America and Europe were
screened for highly-sensitive endomysium or tissue trans-
glutaminase antibodies. Besides, they underwent subse-
quent small intestinal biopsies when antibody testing was
positive. The CD prevalence was found to be much higher
than expected. Approximately 1/100 to 1/500 were found
positive for antibodies and had villous atrophy of the
small intestine [5-10]. Thus, up to 1% of a western popu-
lation tests positive for celiac disease. There are approxi-
mately 7–10 undiagnosed subjects for each known CD
patient. Furthermore, approximately 10% of the first-
degree relatives also have CD [11,12].
Clinical description
Celiac disease is diagnosed typically in early childhood
around age of 2 years. A second peak is found around age
of 40 years [3]. Most symptoms are due to malabsorption
of nutrients and vitamins [13,14]. However, the clinical
manifestations differ greatly, depending on each case and
ranging from asymptomatic (silent) [15] to full blown
(symptomatic, clinically overt) celiac disease [16]. The
severity of symptoms is not necessarily proportional to
the severity of the mucosal lesions and patients with total
villous atrophy can be asymptomatic or present with sub-
clinical symptoms such as iron deficiency or muscle
cramps. Nowadays, more subjects present with asympto-
matic or mild celiac disease than with the classical symp-
toms of severe malabsorption [4,17].
The term "atypical" celiac disease is used for patients who
present with extraintestinal symptoms like Immunoglob-
ulin A (IgA)-nephropathy, hemosiderosis of the lungs and
a variety of neurological diseases. Antibodies and typical
small intestinal changes can be found. Early diagnosis is
desirable since many of these symptoms can disappear
after the initiation of a gluten-free diet.
The term "latent" celiac disease refers to subjects who will
develop the disease later in life but who do not have a flat
mucosa despite a gluten-containing diet [17-20].
Increased intraepithelial lymphocytes (IEL) and positive
endomysium antibody (EMA) or positive tissue trans-
glutaminase (tTG) antibody tests are sometimes found in
these subjects [21-23]. What triggers the onset of the dis-
ease in these subjects remains unknown.
Ferguson et al. introduced the term "potential" celiac dis-
ease in 1993 to characterize in details patients with latent
CD [24]. The authors suggested "potential" CD to be used
Table 1: Definition of different states of celiac disease.
States of celiac disease 
(CD)
Definition
Clinically overt CD Typical gastrointestinal symptoms and signs of malabsorption. Histological changes with villous atrophy and 
hypertrophic crypts (Marsh type-3 lesion, see table 2).
Symptomatic (active) CD Same findings as in clinically overt CD
Silent CD Asymptomatic patients with typical histological changes (Marsh type-3)
Asymptomatic CD Same findings as in silent CD
Atypical CD Extraintestinal findings such as IgA-nephropathy and neurological symptoms. Typical histological changes.
Latent CD/potential CD Subjects with genetic predisposition who have initially a normal histology with no atrophy or crypt hyperplasia. 
Immunological abnormalities such as increased count of IELs (particularly gamma-delta T cells, Marsh type-1) and 
positive EMA or tTG-antibody tests are sometimes present. These subjects may develop clinically overt CD later in 
life.
Refractory CD Patients who do not respond to a gluten-free diet or who previously responded but later become non-responsive to 
a gluten-free diet. Intestinal lymphoma may have developed. Inadvertent gluten ingestion and other diseases must be 
excluded (see differential diagnosis).Orphanet Journal of Rare Diseases 2006, 1:3 http://www.OJRD.com/content/1/1/3
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for the subjects who have markers of latent CD (elevated
IEL, positive for tTG) without ever developing overt CD,
with "latent" CD being used for patients who will develop
a flat mucosa in the future. However, this discrimination
is very artificial and not shared by other specialists in the
field [25]. The terms "latent" and "potential" celiac dis-
ease are not used by all authors in the same way, which
can further confuse matters. Patients with latent or poten-
tial celiac disease may develop symptoms that respond to
a gluten-free diet [26]. For the definition of the different
states of celiac disease, see table 1.
Celiac disease is also associated with several extraintesti-
nal diseases and autoimmune diseases, which can not be
linked to nutrient deficiencies [27-33]. For example, up to
8% of patients with type 1 diabetes were reported to test
positive for CD [4]. CD patients are also at higher risk of
developing malignancies. Holmes et al. reported an
increased risk especially of intestinal lymphoma in sub-
jects with untreated celiac disease compared to patients
on a gluten-free diet [34]. However, more recent data indi-
cate that this risk may be lower than previously antici-
pated [35,36].
The following extraintestinal symptoms are secondary to 
malabsorption [2,3]
• Peripheral neuropathy (vitamin B12 and B1 deficiency)
• Anemia (iron, vitamin B12 and folate deficiency)
• Growth failure in children
• Bone pain (osteoporosis and osteopenia, vitamin D and
calcium deficiency)
• Muscle cramps (magnesium and calcium deficiency)
• Night blindness (vitamin A deficiency)
• Weight loss (impaired absorption of most nutrients)
• Edema (protein and albumin loss)
• Weakness (hypokalemia and electrolyte depletion)
• Bleeding and hematoma (vitamin K deficiency)
The following extraintestinal symptoms/manifestations 
are probably not secondary to malabsorption (atypical 
CD) [27]
• Neurological disorders such as depression, epilepsy,
migraine, ataxia
• Dermatitis herpetiformis
• Elevated liver enzymes, liver failure
• Infertility
• Stomatitis
• IgA nephritis
• Myocarditis
• Idiopathic pulmonary hemosiderosis
• Arthritis
The following diseases/conditions are associated with 
celiac disease [29-31]
• Autoimmune diseases such as type 1 diabetes, Sjögren
syndrome, thyroid diseases (Hashimoto's thyroiditis and
Graves's disease), autoimmune hepatitis and primary bil-
iary cirrhosis
• Selective IgA deficiency
• Turner's syndrome
• Down's syndrome
Diagnostic methods
Firm diagnosis of CD can only be established after small
intestinal biopsies confirming a flat jejunal mucosa with
absence of normal intestinal villi [2,3]. Histological exam-
ination further demonstrates a cellular infiltrate of lamina
propria consisting of plasma cells and lymphocytes [37].
The number of intraepithelial lymphocytes and especially
the number of gamma/delta T cells is markedly increased
(>40 IEL/100 epithelial cells) [38,39]. Small intestinal
changes can vary from a nearly normal mucosa with
increased IEL [40] to a completely flat mucosa [41].
Pathologists write a standardized report to characterize
the histological features of celiac disease [42] (see table 2).
In cases with minor histological changes, a six-week glu-
ten challenge and subsequent endoscopy can be per-
formed. In subjects with negative serology (see below),
diseases other than CD that can cause villous flattening
must be ruled out [1]. Thus, the diagnosis of celiac disease
should not depend only on biopsy, but also the clinical
picture and serology should be considered.
Antibody tests cannot replace histology but are very help-
ful as a screening tool in asymptomatic subjects at higher
risk of developing celiac disease (first-degree relatives and
patients with autoimmune diseases, e.g. diabetes) [43].
Until recently, the determination of IgA endomysium
antibodies was the most important laboratory test in the
diagnosis of CD [3,44]. In some scientific research institu-Orphanet Journal of Rare Diseases 2006, 1:3 http://www.OJRD.com/content/1/1/3
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tions this test reaches a sensitivity and specificity around
97%. However, in routine laboratories, this test is much
less sensitive (giving rise to more false-negative results)
[45,46]. Since frozen sections of monkey esophagus are
used for this assay, it is very expensive. The autoantigen,
which is recognized by endomysium antibodies (EMA), is
now discovered and shown to be tissue transglutaminase
(tTG). Subsequently, several ELISA tests for detection of
tTG antibodies were developed. They have the same sensi-
tivity and specificity as EMA assays [47-49]. Occasionally,
tTG antibodies may detect CD patients undiagnosed by
endomysial antibodies and vice versa [50]. These new tests
are cheaper and the results obtained are much better
reproducible. The first generation of tests used guinea pig
tTG. They were less sensitive and specific [51] than the
new tests that use human transglutaminase [52-54]. How-
ever, the quality of the different tTG-test kits can also dif-
fer markedly [54]. Consequently, strong false positive tTG
results were reported in the clinical practice [55].
For routine diagnosis, the determination of gliadin anti-
bodies are no longer required [56,57]. They are less sensi-
tive and specific than EMA and tTG antibody tests. The
sensitivity of IgA gliadin antibodies is around 80–90%
and the specificity around 85–95%. IgG gliadin antibod-
ies are even less sensitive (75–85%) and specific (75–
90%). However, they allow the detection of patients with
both celiac disease and IgA deficiency. Patients with IgA
deficiency may have negative IgA-gliadin, EMA and tTG
tests. IgA-tTG in combination with IgG-tTG antibody
assays (to detect subjects with IgA deficiency) have fre-
quently replaced all other tests [58-63].
Seroconversion of tTG antibodies after the initiation of a
gluten-free diet is not necessarily accompanied with mor-
phological recovery of the mucosa. After one year of a glu-
ten-free diet a substantial number of celiac patients turned
negative for tissue transglutaminase or endomysial anti-
bodies but still manifested villous atrophy [64,65]. The
normalization of the mucosa can take several years [66].
On the other hand, some patients might have positive tis-
sue transglutaminase antibodies but a completely normal
mucosa. Thus, after the initiation of a gluten-free diet,
antibody tests are not very helpful to draw a conclusion
about the condition of the mucosa. The determination of
IgA-tTG antibodies might be helpful to monitor the suc-
cess of the gluten-free diet [61]. However, others reported
that their negativity is a falsely secure marker of strict diet
compliance [67].
Management including treatment
Two guidelines about the management of CD were
recently published: Recommendations of the North
American Society for Pediatric Gastroenterology, Hepatol-
ogy and Nutrition [56] and National Institutes of Health
(NIH) consensus development conference statement on
celiac disease [68]. Once the diagnosis of celiac disease
has been firmly established (see diagnostic methods), glu-
ten has to be immediately withdrawn. Dietary gluten is
present mainly in wheat, rye and barley [2,41,69]. Since
small amounts of gluten are hidden in many food prod-
ucts, dietary counseling is absolutely necessary. In most
countries, support groups for celiac disease greatly help
patients by providing them with adequate dietary infor-
mation.
Gluten is also found in oats, however many studies sug-
gested that the ingestion of oats is safe for most patients
[70-74]. This data was in line with recent studies, which
failed to identify the toxic amino acid sequences in oats
(see below) [75]. Despite these observations, the inges-
tion of oats can not be endorsed, since commercial oats
are often contaminated with wheat or rye. In addition, the
oats-containing gluten-free diet caused in some individu-
als more intestinal symptoms than the traditional diet.
Rarely, mucosal integrity was disturbed and more inflam-
mation was evident in the group on oats diet. Neverthe-
less, oats may provide an alternative in the gluten-free
diet; at the same time, patients should be aware that the
intestinal symptoms may worsen [76,77]. Antibodies to
oat prolamines were more frequently found higher in
children with CD [76]; however, the significance of this
finding is not clear.
According to the European Society of Pediatric Gastroen-
terology and Nutrition (ESPGAN) criteria, repeated
endoscopy with jejunal biopsy is not necessary if the
patient's condition improves after introducing a gluten-
free diet [78]. The results of repeated endoscopy could be
rather confusing since normalization of the histology may
take up to eight years [66]. At the same time, persistent
mucosal abnormalities were described despite a strict glu-
Table 2: The modified Marsh classification [42].
Type 0 Type 1 Type 2 Type 3a Type 3b Type 3c
IEL <40 >40 >40 >40 >40 >40
Crypts Normal Normal Hypertrophic Hypertrophic Hypertrophic Hypertrophic
Villi Normal Normal Normal Mild atrophy Marked atrophy Absent
* Numbers are given as intraepithelial lymphocytes (IEL)/100 epithelial cellsOrphanet Journal of Rare Diseases 2006, 1:3 http://www.OJRD.com/content/1/1/3
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ten-free diet [79,80]. Thus, there is no point in repeating
endoscopy when the patient improves on a gluten-free
diet. Vitamin supplementation may be necessary at the
beginning of a gluten-free diet in subjects with severe
celiac disease. Patients with clinically overt CD should go
on a strict gluten-free diet since those not treated are at a
higher risk of malignancies [34], anemia and osteoporosis
[13,17,81]. In addition, the onset of autoimmune dis-
eases which are associated with celiac disease seem to be
related to the duration of exposure to gluten [82]. How-
ever, this issue is controversial especially in adults: nega-
tive reports have been published in Italy and Finland
[83,84].
In subjects who do not respond to a gluten-free diet, non
compliance or inadvertent ingestion of gluten should be
considered [85]. Microscopic colitis in patients with per-
sistent diarrhea should be ruled out by colonoscopy [86].
Small intestinal bacterial overgrowth was reported to be
frequently present in CD [87]. Patients with this condi-
tion can be identified by a hydrogen breath tests (H2
breath test). They rapidly improve after the initiation of an
antibiotic regimen. When these conditions are ruled out,
other diseases such as intestinal lymphoma [88] or refrac-
tory sprue should be envisaged [89].
Whether asymptomatic screen-detected patients (with
normal laboratory values and no gastrointestinal symp-
toms) should adhere to a gluten-free diet remains a con-
troversial issue [90,91]. Some authors suggest the silent
cases of CD to be treated with a life long gluten-free diet,
otherwise they are exposed to the risks of long-term com-
plications. On the other hand, 1) until now, no study has
proven the benefit of a gluten-free diet for this subgroup
of patients; 2) the compliance of these subjects to follow
a gluten-free diet is known to be very low; 3) the relative
risks for lymphomas and gastrointestinal cancers in
patients with CD was found lower than previously
thought [35,92,93] with no elevated cancer risk during
childhood and adolescence [35,36].
Etiology
Celiac disease develops in patients who have ingested glu-
ten, which is present in wheat, rye and barley (recent
reviews: [2-4]). Gluten proteins are grouped into high
molecular weight (HMW) glutenins, low molecular
weight (LMW) glutenins and alpha-, gamma- and omega-
gliadins (based on their differential N-terminal sequence,
electrophoresis size and mobility) [94]. Until recently it
was thought that the toxic proteins causing CD are not
present in the HMW glutenins. In consequence, develop-
ment of non-toxic HMW glutenins-containing food prod-
ucts was proposed (e.g. transgenic food). However, recent
evidence showed that there is no group of gluten proteins
safe for patients with CD [94]. Interestingly, gluten
extracted from several ancient wheat species was reported
incapable to stimulate T cell lines (previously shown to be
responsive to toxic gliadin fragments) (see below) [95].
These findings raise the prospect of identifying bred wheat
species with low or absent levels of harmful gluten pro-
teins.
Based on the high association between human leukocyte
antigens (HLA) and celiac disease (over 95%) [96], it is
thought that HLA-DQ2 positive antigen-presenting cells
have gliadin peptides toxic to CD4+ T cells. CD4+ T cells
drive the immune response and damage the mucosa [97-
102]. Tissue transglutaminase (tTG) was identified as the
autoantigen, which is recognized by the endomysial anti-
bodies [57,103] (see below).
Tissue transglutaminase, an enzyme essential in wound
healing for all individuals, was shown to be able to deam-
idate gliadin peptides in vitro [98-101]. The modified glia-
din peptides bind much better to HLA-DQ2 and elicit a
stronger T cell response. Furthermore, gliadin is one of the
main substrates of tTG. It was reported that several pep-
tides can be cross-linked and that tTG itself can be incor-
porated into HMW complexes. These newly generated
molecules are potential "neo"-autoantigens, which might
be responsible for the induction of a destructive immune
response.
Gliadin-reactive CD4+ T cells were isolated from the intes-
tinal mucosa of patients with celiac disease [97]. These T
cells can elicit a B cell response with production of auto-
reactive antibodies against gliadin peptides or tTG. How-
ever, whether the role of these antibodies is significant
[104] or whether they have a pathogenic role in celiac dis-
ease remains unknown [105]. It also remains unknown
why tTG or gliadin complexes are recognized only by T
cells from celiac patients and not by those from healthy
HLA-DQ2 positive subjects. In addition, the increase in
CD8+ T cells in the epithelium of the mucosa (IEL) cannot
be explained by HLA-DQ2 positive cells, which only acti-
vate CD4+ T cells. Additional factors like infections,
which damage the mucosa may trigger the onset of the
disease in predisposed individuals.
In recent years, considerable progress has been made in
identifying the amino acid sequences of gliadin peptides
that may trigger CD. From these studies it became evident
that there is not just one peptide but many gliadin pep-
tides, which are capable to stimulate T cell lines from
patients with CD [106-109]. All toxic gliadin fragments
had a high content of the amino acid proline
[75,106,107]. A "super" gliadin 33 amino acids peptide,
capable to stimulate all gliadin specific T cell lines in a
very vigorous manner, has been identified by the group of
Shan L et al. [110]. This gliadin fragment is rich in prolineOrphanet Journal of Rare Diseases 2006, 1:3 http://www.OJRD.com/content/1/1/3
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and contains multiple short amino acid sequences, which
were previously shown to stimulate T cell lines [106,111-
113]. In addition, this peptide was completely resistant to
the breakdown of endogenous proteases and peptidases,
indicating that the full length fragment can reach the
small intestine and stimulate mucosal T cells. The same
research group described a bacterial prolyl endopeptidase
(from Flavobacterium meningosepticum), which is capable
to digest in vitro all proline rich peptides, including the 33
amino acid long "super" gliadin fragment [114]. The
authors suggested that patients with celiac disease might
be able to tolerate gluten by supplementing the food with
this enzyme. Currently, this hypothesis is under investiga-
tion (see Celiac Sprue Research Foundation [115]; Gluten
detoxification trial). However, it is unlikely that all toxic
gluten peptides would be efficiently destroyed, so this
enzyme treatment would fail to prevent the gluten toxicity
completely [108,116].
Genetic counseling
Celiac disease is associated with HLA-DQ2/DQ8 in over
95% of the cases [102]. However, 20% of the healthy pop-
ulation carry the same gene and will never develop celiac
disease. Thus, no genetic test which could identify "celiac
genes" is currently available. Furthermore, there is no
need for genetic screening since celiac disease can be
treated by a specific diet and patients usually enjoy a good
quality of life and a normal life expectancy. In subjects
with uncertain diagnosis of CD, the determination of the
HLA genes might be helpful [117]. HLA-DQ2/DQ8 nega-
tive subjects are highly unlikely to suffer from CD.
Unresolved questions
Celiac disease is the only autoimmune disease in which
the agents that trigger the disease are identified, i.e. glia-
din, the autoantigen transglutaminase and even the HLA-
genes (DQ2/DQ8) which are associated with the disease.
However, the exact mechanisms damaging the intestinal
mucosa and the exact role of autoantibodies such as tTG
and EMA antibodies in the pathogenesis of the disease
remains unsolved. Furthermore, the question of how
much gluten is toxic (e.g. trace amounts of contaminated
gluten) is also a matter of discussion in both Europe and
USA.
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